FPC
MYGN icon

Falcon Point Capital’s Myriad Genetics MYGN Stock Holding History

Falcon Point Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-71,927
Closed -$2.09M – 108
2018
Q4 		$2.09M Buy
+71,927
New +$2.59M 1.25% 36

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Falcon Point Capital's MYGN Position: Q1 2019 in Review

Falcon Point Capital sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 71,927 shares — an estimated $2.09M sold.

Falcon Point Capital first reported a position in MYGN in Q4 2018 and held it in 1 quarter. The position peaked at $2.09M in Q4 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

  • Falcon Point Capital reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
  • Falcon Point Capital sold 71,927 Myriad Genetics shares in Q1 2019, an estimated $2.09M.
  • Falcon Point Capital first reported a position in Myriad Genetics in Q4 2018 and held it in 1 quarter.
  • Falcon Point Capital's Myriad Genetics position peaked at $2.09M in Q4 2018.
  • 262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Falcon Point Capital's 13F filing for Q1 2019, filed 8 May 2019.